Mirae Asset Global ETFs Holdings’s Sage Therapeutics SAGE Stock Holding History

Mirae Asset Global ETFs Holdings’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-31,380	Closed	-$286K	–	3146
2025 Q2	$286K	Sell	31,380 -1,404	-4%	-$10.3K	﹤0.01%	2090
2025 Q1	$261K	Buy	32,784 +1,404	+4%	+$10.3K	﹤0.01%	2183
2024 Q4	$170K	Sell	31,380 -4,166	-12%	-$25.5K	﹤0.01%	2462
2024 Q3	$257K	Buy	35,546 +4,874	+16%	+$44.6K	﹤0.01%	2244
2024 Q2	$332K	Buy	+30,672	New	+$393K	﹤0.01%	2010

Other funds holding SAGE

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Mirae Asset Global ETFs Holdings's SAGE Position: Q3 2025 in Review

Mirae Asset Global ETFs Holdings sold out of Sage Therapeutics (SAGE) in Q3 2025, closing a stake of 31,380 shares — an estimated $286K sold.

Mirae Asset Global ETFs Holdings first reported a position in SAGE in Q2 2024 and held it in 5 quarters. The position peaked at $332K in Q2 2024. 5 funds tracked by Wall St. Rank hold SAGE as of Q3 2025.

Mirae Asset Global ETFs Holdings reported no remaining Sage Therapeutics position as of Q3 2025 after selling out during the quarter.
Mirae Asset Global ETFs Holdings sold 31,380 Sage Therapeutics shares in Q3 2025, an estimated $286K.
Mirae Asset Global ETFs Holdings first reported a position in Sage Therapeutics in Q2 2024 and held it in 5 quarters.
Mirae Asset Global ETFs Holdings's Sage Therapeutics position peaked at $332K in Q2 2024.
5 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2025.

Based on Mirae Asset Global ETFs Holdings's 13F filing for Q3 2025, filed 14 Nov 2025.